NKGen Biotech, Inc. Common Stock
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Paul Y. Song
- Full Time Employees
- 63
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3001 Daimler Street Santa Ana CA United States of America 92705
- IPO Date
- Oct 2, 2023
- CIK
- 0001845459
- Website
- nkgenbiotech.com
- Similar Companies
- Business
- NKGen Biotech, Inc. is a clinical-stage biotechnology company focused on developing and commercializing innovative cell therapies, specializing in autologous, allogeneic, and CAR-NK natural killer (NK) cell therapies for neurodegenerative and oncological diseases. Its core products include the proprietary SNK (super-activated) platform and lead therapeutic candidate troculeucel, an autologous enhanced NK cell therapy targeting Alzheimer's disease which has received FDA fast track designation and demonstrated promising clinical efficacy. The company operates globally, leveraging manufacturing infrastructure and intellectual property assets through its majority-owned Korean affiliate, NKGen Korea (formerly NKMax Co., Ltd.). Founded as a subsidiary of NKMax in 2017 and headquartered in Santa Ana, California, NKGen recently completed a strategic acquisition of a 65% controlling stake in NKMax Co., Ltd. in 2025, gaining full control over global manufacturing, IP, and commercialization rights. This acquisition marks a major strategic shift, positioning NKGen as a fully integrated cell therapy company with enhanced capabilities to advance its pipeline and expand its market presence. Additionally, the company has received FDA authorization for an Expanded Access Program for troculeucel, allowing treatment of patients with various neurodegenerative diseases beyond ongoing clinical trials. NKGen also engages in partnerships and capital infusions that support its clinical development and commercialization strategies in the biotechnology and cell therapy sector.
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support Enrollment
NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026
Head to Head Contrast: NKGen Biotech (NYSE:NKGN) and SQZ Biotechnologies (NYSE:SQZ)
Head to Head Comparison: NKGen Biotech (NYSE:NKGN) versus SQZ Biotechnologies (NYSE:SQZ)
NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D.
Analyzing Genocea Biosciences (NASDAQ:GNCA) and NKGen Biotech (NYSE:NKGN)
Sorrento Therapeutics (NASDAQ:SRNE) versus NKGen Biotech (NYSE:NKGN) Head-To-Head Review
NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets
NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit
NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025
NKGen Biotech to Present at the Alzheimer's Association International Conference 2025
NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan
NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards
NKGen Biotech Administers First Dose of Troculeucel to Alzheimer's Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy
NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer's Trial with Activation of Clinical Sites in Canada and Florida